What is it about?
This paper examines the role of extracellular vesicles (EVs) in regenerative medicine, focusing on their potential to treat degenerative diseases. Current research indicates that intravenously administered EVs are primarily sequestered in the liver, spleen, and lungs. To optimize therapeutic efficacy and minimize off-target effects, recent studies are exploring diverse bioengineering strategies to enhance tissue-specific targeting. Authors review the existing strategies for in vivo tracking and targeting of EVs isolated from different cellular sources and the studies elucidating the biodistribution of exogenously administered EVs for therapeutic purposes
Featured Image
Photo by Duangphorn Wiriya on Unsplash
Read the Original
This page is a summary of: Towards Therapeutic Delivery of Extracellular Vesicles: Strategies forIn VivoTracking and Biodistribution Analysis, Stem Cells International, January 2016, Hindawi Publishing Corporation,
DOI: 10.1155/2016/5029619.
You can read the full text:
Resources
Towards Therapeutic Delivery of Extracellular Vesicles: Strategies for In Vivo Tracking and Biodistribution Analysis
Open Access Version Full Text Html
Stem Cell Research; Researchers at Regina Elena Cancer Institute Report New Data on Stem Cell Research
NewsRX
Towards Therapeutic Delivery of Extracellular Vesicles
Exosome RNA Research and Industry News
Extracellular Vesicles–Encapsulated MicroRNA-125b Produced in Genetically Modified Mesenchymal Stromal Cells Inhibits Hepatocellular Carcinoma Cell Proliferation
Cells ( 2019) 8(12): 1560. doi: 10.3390/cells8121560.
Contributors
The following have contributed to this page
